Sartans are very effective drugs for treatment of hypertension, heart failure, and other cardiovascular disorders. They antagonize the effects of angiotensin II at the AT 1 receptor and display p.o. bioavailability rates of 13 to 80%. Because some sartans sterically resemble dipeptide derivatives, we investigated whether they are transported by peptide transporters. We first assessed the effects of sartans on . In contrast to cefadroxil, no PEPT1-specific uptake of valsartan and losartan was found. We conclude that the sartans tested in this study display high-affinity interaction with PEPTs but are not transported themselves. However, they strongly inhibit hPEPT1-mediated uptake of dipeptides and cefadroxil.
Sartans such as losartan, valsartan, irbesartan, and eprosartan are blockers of the angiotensin II type 1 receptor. They have proven to be effective in the treatment of hypertension, renal diseases, heart failure, ventricular hypertrophy, dilation, arrhythmias, and dysfunction with overall reduced cardiovascular morbidity and mortality and fewer negative side effects than the classic angiotensin-converting enzyme inhibitors (for review, see Perico and Remuzzi, 1998; Jack, 2000; Jugdutt, 2006; Ramasubbu et al., 2007) . Valsartan gained considerable interest last year when Wang et al. (2007) discovered that it lowers brain ␤-amyloid protein levels in a mouse model and significantly reduces Alzheimer's disease-type neuropathology and cognitive deterioration, even when delivered at a dose lower than that used for hypertension treatment in humans.
After p.o. administration as the primary route, sartans display bioavailability levels in the range of 13% (eprosartan) to 80% (irbesartan) (Dominiak, 1999) . Because some sartans sterically resemble dipeptide and tripeptide derivatives, the question arises whether these drugs interact with peptide transporters. Dipeptides and tripeptides are taken up into intestinal cells by the low-affinity H ϩ /peptide cotransporter (PEPT) 1. In the kidney tubule, dipeptides and tripeptides are reabsorbed mainly by the high-affinity PEPT2 (for review, see Daniel and Kottra, 2004; Brandsch et al., 2008) . Ekins et al. (2005) , when searching the Comprehensive Medicinal Chemistry database in a pharmacophore-based approach for new human PEPT1 (hPEPT1) ligands, retrieved-among many other drugs-losartan as a possible substrate or inhibitor of hPEPT1. Transport of sartans by peptide transporters could explain their p.o. bioavailabilities and their renal reabsorption. On the other hand, high-affinity inhibition of peptide transporters may have consequences for the absorption of peptides and drugs that are peptide transporter substrates, such as p.o. ␤-lactam antibiotics or valacyclovir.
Materials and Methods
Materials. The human cell lines Caco-2 and HeLa were obtained from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany) . The rat renal cell line SKPT was provided by U. Hopfer (Case Western Reserve University, Cleveland, OH). pBluescript II SK(Ϫ), pBluescript-hPEPT1, and pBluescript-hPEPT2 were donations of V. Ganapathy (Medical College of Georgia, Augusta, GA). [Glycine-1-14 C]glycylsarcosine ([ 14 C]Gly-Sar) (specific radioactivity 53 mCi/mmol) was custom-synthesized by GE Healthcare Bio-Sciences (Little Chalfont, Buckinghamshire, UK). GlySar, Gly-Gln, cefadroxil, and cephalexin were from Sigma-Aldrich (Deisenhofen, Germany). Eprosartan was from Solvay (Hanover, Germany); irbesartan was from sanofi-aventis (Chilly-Mazarin, France); losartan was from MSD Sharp and Dohme (Haar, Germany); and valsartan was from Novartis (Basel, Switzerland).
Culture of Caco-2 and SKPT Cells and Uptake Studies. Caco-2 and SKPT cells were cultured as described previously (Theis et al., 2002; Knütter et al., 2004; Luckner and Brandsch, 2005) . Both lines were subcultured in 35-mm disposable Petri dishes (Sarstedt, Nümbrecht, Germany) at a seeding density of 0.8 ϫ 10 6 cells/dish. Uptake of [ 14 C]Gly-Sar was measured 4 days (SKPT) or 7 days (Caco-2) after seeding. Uptake buffer was 25 mM Mes/Tris, pH 6.0, containing 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl 2 , 0.8 mM MgSO 4 , 5 mM glucose, [
14 C]Gly-Sar (10 M), and unlabeled sartans (0 -3.16 mM, pH readjusted if necessary). After incubation for 10 min, the monolayers were quickly washed four times with ice-cold uptake buffer, solubilized, and prepared for liquid scintillation spectrometry. Transepithelial flux of [ 14 C]GlySar across Caco-2 cell monolayers cultured on permeable filters was measured as described previously (Neumann et al., 2004) . After washing the inserts at pH 7.5 for 10 min, uptake at 37°C was started by adding 1.5 ml of uptake buffer, pH 6.0, containing [ 14 C]Gly-Sar with or without 1 mM sartan to the donor side. Samples were taken from the receiver compartment (2.6 ml of buffer, pH 7.5) and replaced with fresh buffer. The radioactivity in the samples was measured by liquid scintillation spectrometry. After 2 h, the filters supporting the monolayers were quickly washed four times with ice-cold uptake buffer, cut out of the plastic insert, and transferred to scintillation vials.
Xenopus laevis Oocytes Expressing PEPT1 and PEPT2 and Electrophysiology. Surgically removed oocytes from female X. laevis (African Xenopus Facility, Knysna, South Africa) were separated by collagenase treatment and were injected with 30 nl of RNA solution containing 30 ng of rabbit PEPT1 or rabbit PEPT2 cRNA (Theis et al., 2002; Knütter et al., 2004) . After 3 to 6 days, the two-electrode voltage-clamp technique was applied to characterize responses in current (I) to substrate addition (1 mM). Current-voltage (I-V m ) relationships were measured in the potential range from Ϫ160 to ϩ80 mV. I-V m measurements were made immediately before and 30 s after substrate application when current flow reached steady state.
Heterologous Expression of hPEPT1 and hPEPT2 in HeLa Cells and Uptake Studies. HeLa cells were routinely cultured with Dulbecco's minimum essential medium with GlutaMAX (Invitrogen GmbH, Karlsruhe, Germany) supplemented with 10% fetal bovine serum and gentamicin (45 g/ml). The cDNA of human PEPT1 and PEPT2 was cloned into pcDNA3 using the pBluescript constructs as a template for the polymerase chain reaction and XhoI and BamHI as restriction sites. The resulting pcDNA3-hPEPT1/2 constructs were confirmed by sequencing. hPEPT1 and hPEPT2 were heterologously expressed in HeLa cells using pcDNA3 hPEPT1 or hPEPT2 cDNA constructs (1 g/well) and Turbofect (1.5 l/well; Fermentas, St. Leon-Rot, Germany) according to manufacturers' protocols. The transfection was done 1 h postseeding in 24-well plates, and 20-to 24-h post-transfection uptake of [ 14 C]Gly-Sar (20 M, pH 6.0) in the absence or presence of increasing concentrations of Gly-Sar, valsartan, or losartan was measured at room temperature. After incubation for 10 min, the monolayers were quickly washed four times with ice-cold uptake buffer, solubilized, and prepared for liquid scintillation spectrometry. Transfected HeLa cells were also used for uptake studies with the unlabeled drugs. Cells were incubated with unlabeled cefadroxil, losartan, or valsartan (1 mM) at pH 6.0 for 30 min at room temperature. Subsequently, the monolayers were quickly washed four times with ice-cold uptake buffer, and 500 l of double-distilled water was added. After freezing and thawing three times, the resulting suspension was transferred to 1.5-ml tubes, homogenized with a 25-gauge needle, and centrifuged in a table-top centrifuge at 13,000 rpm for 45 min. The supernatant was centrifuged again at 13,000 rpm for 45 min and prepared for high-performance liquid chromatography (HPLC) measurements.
HPLC Measurements. Samples were analyzed according to the laboratory standard HPLC (La-Chrom; Merck-Hitachi, Darmstadt, Germany) with a diode array detector and a Purospher STAR RP-18 end-capped column (125-4, 5 m; Merck, Darmstadt, Germany). The eluent was 45% acetonitrile/55% H 2 O with 0.1% trifluoroacetic acid, pH 1.9, for losartan and valsartan and 15% acetonitrile/ 85% H 2 O with 0.1% trifluoroacetic acid, pH 1.9, for cefadroxil. UV-detection was done at 232 nm; the injection volume was 20 l; the flow rate was 0.75 ml/min; and the column temperature was 34°C. Cephalexin was used as internal standard for cefadroxil, whereas losartan was used as internal standard for valsartan and vice versa. The retention time was between 2.5 and 8 min.
Calculations and Statistics. All of the data are given as the mean Ϯ S.E. of three to five independent experiments. The kinetic parameters were calculated by nonlinear regression methods and confirmed by linear regression of the respective Eadie-Hofstee plots. IC 50 values (i.e., concentration of the unlabeled sartans or dipeptides necessary to inhibit 50% of carrier-mediated [ 14 C]Gly-Sar uptake) were determined by nonlinear regression using the logistical equation for an asymmetric sigmoid (allosteric Hill kinetics):
, where Max is the initial y value, Min the final y value, and the power P represents Hill coefficient. Inhibition constants (K i ) were calculated from IC 50 values according to the method developed by Cheng and Prusoff (1973) .
Results

Inhibition of [
14 C]Gly-Sar Transport at Caco-2 and SKPT Cells by Sartans. We studied the interaction of the four sartans-losartan, irbesartan, valsartan, and eprosartan-with PEPT1 and PEPT2 in competition assays using [ 14 C]Gly-Sar as a reference substrate. The intestinal cell line Caco-2 constitutively expressing PEPT1 (Knütter et al., 2004; Neumann et al., 2004 ) and the renal cell line SKPT constitutively expressing PEPT2 (Theis et al., 2002; Luckner and Brandsch, 2005) were used. Uptake of [ 14 C]Gly-Sar into Caco-2 cells in the presence of an inwardly directed H ϩ gradient showed concentration-dependent inhibition by losartan, irbesartan, valsartan, and eprosartan (Fig. 1A) . From the Gly-Sar (20 M) was added to the apical (donor) compartment of the Transwell chambers in uptake buffer, pH 6.0, with or without 1 mM sartan. After the time intervals indicated, samples were taken from the receiver compartment, pH 7.5, and replaced with buffer. Inset, [
14 C]Gly-Sar content in cells on filters cut out of the plastic inserts after the flux measurements. Data are shown as means Ϯ S.E., n ϭ 3. competition curves we calculated K i values between 24 M and 2.2 mM ( Table 1 ). The competitor with the highest affinity was losartan followed by irbesartan, valsartan, and eprosartan. At SKPT cells the four sartans also inhibited [ 14 C]Gly-Sar uptake with K i values ranging between 2.2 M and 0.49 mM ( Fig. 1A ; Table 1 ). To rule out unspecific effects on cell membrane integrity or on the proton gradient as the driving force for Gly-Sar uptake, we also studied the effect of sartans on proton-coupled [ 3 H]proline transport (Metzner et al., 2008) . Eprosartan, losartan, and valsartan (1 mM) did not affect [ 3 H]proline uptake at Caco-2 cells (97.9 Ϯ 4.3, 83.0 Ϯ 3.8, and 94.9 Ϯ 1.2% of control, respectively).
Caco-2 cells were also cultured for 21 days on permeable filter membranes in Transwell chambers. With this technique, we measured the total transepithelial [ 14 C]Gly-Sar flux across cell monolayers at pH 6.0 in the absence or presence of unlabeled sartans (Fig. 1B) . The mean transepithelial electrical resistance of the Caco-2 cell monolayers at the day of the experiment was 576 Ϯ 11 ⍀ ⅐ cm 2 . The transepithelial [
14 C]Gly-Sar flux (20 M, control) was 1.48 Ϯ 0.1% ⅐ h Ϫ1 ⅐ cm Ϫ2 , which is in agreement with previously published values (Neumann et al., 2004) . In the presence of losartan, valsartan, and eprosartan (1 mM), the [ 14 C]Gly-Sar flux was decreased to 0.23 Ϯ 0.01, 0.93 Ϯ 0.05, and 1.31 Ϯ 0.1% ⅐ h Ϫ1 ⅐ cm Ϫ2 , respectively (Fig.  1B) . The same rank order of inhibition was observed when the [ 14 C]Gly-Sar contents in cells after completion of the flux measurements (2 h) were analyzed (Fig. 1B, inset) . The The calculation of IC 50 values by nonlinear regression revealed Hill coefficients of approximately 1 for all the inhibition data, as is expected for competitive inhibition. To determine the effects of sartans on the kinetic parameters of Gly-Sar uptake, we studied the relationship between the Gly-Sar uptake rates and extracellular Gly- 
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Sar concentration in Caco-2 (Fig. 2 , A and C) and SKPT (Fig. 2, B and D) cells. In the absence of valsartan, the Michaelis constant, K t , of Gly-Sar uptake at Caco-2 cells was 1.1 Ϯ 0.1 mM, and the maximal velocity of uptake (V max ) was 39.4 Ϯ 1.0 nmol ⅐ mg protein Ϫ1 /10 min ( Fig. 2A) . The corresponding kinetic constants obtained in the presence of 0.5 mM valsartan were (K t ) 3.2 Ϯ 0.4 mM and (V max ) 46.3 Ϯ 2.3 nmol ⅐ mg protein Ϫ1 /10 min. Hence, valsartan at a concentration close to its K i value increased the K t value of Gly-Sar uptake by approximately 3-fold, whereas the V max value was not altered significantly. For SKPT cells, the K t value of Gly-Sar uptake was 0.14 Ϯ 0.02 mM and the V max value was 6.9 Ϯ 0.3 nmol ⅐ mg protein Ϫ1 /10 min (Fig. 2B) . The corresponding kinetic constants obtained in the presence of 0.4 mM valsartan were (K t ) 0.28 Ϯ 0.03 mM and (V max ) 6.13 Ϯ 0.09 nmol ⅐ mg protein Ϫ1 /10 min. Valsartan thereby increased the K t of Gly-Sar uptake by PEPT2 also 2-fold without affecting V max . Likewise, losartan at a concentration of 50 and 5 M, respectively, increased the K t values of Gly-Sar uptake 2.5-fold at Caco-2 cells and 2-fold at SKPT cells without affecting the V max value (Fig. 2, C and  D, insets) .
Two-Electrode Voltage-Clamp Technique in X. laevis Oocytes Expressing PEPT1 or PEPT2. Inhibition of [
14 C]Gly-Sar uptake does not necessarily mean that the sartans themselves are transported by peptide transporters. To assess their possible transport by PEPT1 and PEPT2, the two-electrode voltage-clamp technique with X. laevis oocytes expressing the PEPTs was applied (Theis et al., 2002; Knütter et al., 2004) . In contrast to transporter substrates, no currents were observed for any of the sartans (Fig. 3, A and B) . The currents elicited by the four sartans (1 mM) are expressed as percentage of the current induced by the dipeptide Gly-Gln (1 mM) measured in the same oocyte (Fig. 3B) . In Fig. 3 , C and D, representative currents elicited by Gly-Gln and losartan for PEPT1 and PEPT2 as a function of membrane potential are shown. Losartan-despite its very high affinity for PEPT1 and PEPT2-failed to evoke any currents, whereas Gly-Gln (1 mM) caused high inward currents. More importantly, the currents evoked by Gly-Gln were strongly inhibited by losartan. Moreover, this inhibition was fully reversible, i.e., washing the oocyte and adding Gly-Gln again completely restored the inward-directed currents.
Uptake of Losartan and Valsartan in HeLa-hPEPT1 and HeLahPEPT2 Cells and Their Effect on Cefadroxil Uptake. The inhibition of dipeptide uptake by losartan and valsartan was also studied in competition assays with hPEPT1 and hPEPT2 heterologously expressed in HeLa cells (Fig. 4A) . Again, Electrophysiological measurements at PEPT1-and PEPT2-expressing oocytes only detect electrogenic transport of substrates. Electroneutral transport of the four sartans by PEPT1 and PEPT2 could not be ruled out. Therefore, in the next series of experiments, we directly measured the uptake of losartan and valsartan into HeLapcDNA3 and HeLa-hPEPT1 cells (Fig. 4B) . The PEPT1 substrate cefadroxil served as positive control. The cells were incubated with valsartan, losartan, or cefadroxil at a concentration of 1 mM for 30 min, washed, and solubilized. The intracellular drug concentrations were determined by quantitative HPLC. Compared with the uptake of cefadroxil, uptake of valsartan, and in particular of losartan, was high, but more importantly, there was no difference between cells transfected with empty vector and cells transfected with hPEPT1. In contrast, cefadroxil is accumulated at least 30-fold in hPEPT1-HeLa cells compared with mock cells (Fig. 4B) . However, losartan and valsartan at a concentration of 1 mM were able to inhibit the hPEPT1-mediated cefadroxil uptake (1 mM) strongly by 87 and 69%, respectively (Fig. 4C) .
Discussion
In this study, we investigated systematically whether the sartans losartan, irbesartan, valsartan, and eprosartan interact with PEPT1 and PEPT2. First, we studied the effect of the drugs on the transport of a reference dipeptide, Gly-Sar, into human intestinal cells (Caco-2) and rat renal cells (SKPT) expressing PEPT1 or PEPT2, respectively (Theis et al., 2002; Knütter et al., 2004; Neumann et al., 2004; Luckner and Brandsch, 2005) . Losartan, irbesartan, valsartan, and eprosartan inhibited [
14 C]Gly-Sar uptake into Caco-2 cells in a competitive manner with K i values of 24, 230, 390, and Ͼ1000 M. The affinity constants of prototype substrates of PEPT1 (dipeptides and tripeptides) are typically in the range of 100 M to 1 mM. The K i PEPT1 of Ala-Pro, for example, measured under identical conditions is 140 Ϯ 10 M . Therefore, the sartans tested in this study interact with PEPT1 with affinities similar to those of natural dipeptide substrates. According to our classification of PEPT1 substrates and inhibitors , losartan, irbesartan, and valsartan are considered as high-affinity ligands.
In SKPT cells, [ 14 C]Gly-Sar uptake was inhibited with K i values of 2.2 M (losartan), 65 M (irbesartan), 260 M (valsartan), and 490 M (eprosartan). For comparison, the K i PEPT2 of Ala-Pro is 14 Ϯ 1   FIG. 3 . Sartan-induced inward currents in X. laevis oocytes expressing PEPT1 or PEPT2. A, typical recordings of inward currents in oocytes expressing PEPT1 (Ϫ60 mV) in the presence of 1 mM Gly-Gln, valsartan, and irbesartan. B, currents induced by losartan, irbesartan, valsartan, and eprosartan as the percentage of the current induced by 1 mM Gly-Gln (PEPT1, Ϫ60 mV; PEPT2, Ϫ160 mV; n ϭ 4 -13). C and D, steady-state I-V m relationships were measured by the two-electrode voltage-clamp technique in oocytes expressing PEPT1 (C) or PEPT2 (D) superfused with modified Barth solution at pH 6.5 and 1 mM losartan and/or 1 mM Gly-Gln. The membrane potential was stepped symmetrically to the test potentials shown, and substrate-dependent currents were recorded as the difference measured in the absence and the presence of substrates. NI oocyte, noninjected oocyte.
M . Again, losartan displayed the highest affinity. According to our classification of PEPT2 substrates and inhibitors , losartan and irbesartan are highaffinity ligands, and valsartan and eprosartan interact with medium affinity. Comparing the rank order of compounds for Gly-Sar uptake inhibition we conclude that there are no major differences in the sartan recognition pattern between hPEPT1 and rat PEPT2. The higher affinity of most compounds to PEPT2 compared with PEPT1 is a well known phenomenon.
The results obtained at HeLa cells expressing human PEPT1 and human PEPT2 confirmed the inhibition constants measured at intestinal or renal cells and rule out that the differences in affinity constants between hPEPT1 and rat PEPT2 are the result of species differences. The result that sartans do not inhibit [ 3 H]proline uptake at Caco-2 cells rules out the possibility that their effects on Gly-Sar transport are because of effects on cell membrane integrity or on the proton gradient as the driving force for PEPT1 and PEPT2. At the same time, the results show that sartans are no substrates for the proton-coupled amino acid cotransporter hPAT1 (Metzner et al., 2008) .
Our results suggest a competitive type of inhibition of Gly-Sar uptake by the sartans. First, the calculation of IC 50 values by nonlinear regression revealed Hill coefficients of approximately 1 for all of the inhibition data, as is expected for competitive inhibition. Second, valsartan and losartan only affected the K t value of Gly-Sar transport but not the V max . Therefore, the sartans are acting either as competing transporter substrates or as nontransported competitive inhibitors. To decide this question, we applied the two-electrode voltage-clamp technique with X. laevis oocytes expressing either PEPT1 or PEPT2. Because of the cotransport with H ϩ , transport of substrates usually elicits inwardly directed currents (Theis et al., 2002; Daniel and Kottra, 2004; Knütter et al., 2008) . It is interesting to note that all four sartans failed to elicit any significant currents. Hence, they are not transported by PEPT1 or PEPT2 in an electrogenic manner. However, the voltage-dependent inward currents induced by Gly-Gln uptake were strongly inhibited by the sartans. This inhibition was fully reversible, suggesting again a competitive mode of action.
Theoretically, the possibility exists that sartans are transported by PEPT1 and PEPT2 in an electroneutral manner. In other words, so far we could not rule out that sartans are taken up by the H ϩ /peptide cotransporters without a net charge (H ϩ ) crossing the oocyte membrane. Therefore, in a third approach, we measured directly by HPLC analysis the PEPT1-specific uptake of losartan and valsartan into HeLa cells expressing human PEPT1. There was no difference between cells transfected with empty vector and cells transfected with hPEPT1. Losartan and valsartan are not transported by PEPT1, in contrast to cefadroxil.
Compared with the uptake of cefadroxil, where uptake in mock cells was below HPLC quantification limit, the uptake rates of valsartan, and in particular uptake of losartan, were quite high. This might be because of the much higher lipophilicity of the sartans compared with cefadroxil. Simple transcellular diffusion could perhaps even explain the p.o. bioavailability of sartans. Alternatively, the question arises whether sartans, if not transported by PEPT1, are substrates for other membrane transport systems. Results published by Yamashiro et al. (2006) and Yamada et al. (2007) suggest that organic anion-transporting polypeptides 1B1 and 1B3, organic anion transporters (OATs)1 and OAT3, multidrug resistance-associated protein 2, and other systems contribute to hepatic and renal transport of olmesartan and valsartan. According to Edwards et al. (1999) , the four sartans studied here are secreted in the kidney by a carrier similar, if not identical, to the classic para-aminohippurate transporter (OATs). The intestinal absorption of sartans via such transport systems should be investigated in the future. With regard to efflux back into the intestinal lumen, it is relevant that losartan has been shown to be a P-glycoprotein substrate (Young et al., 2006) .
Our results obtained in this study regarding the interaction of sartans with peptide transporters suggest that the sartans interact with PEPT1 and PEPT2 with high affinity but are not transported themselves. Their p.o. bioavailability cannot be explained by the activity of PEPT1. However, the high-affinity interaction with PEPT1 and PEPT2 might have consequences for the absorption of other drugs that are substrates of PEPT1. We have shown here that losartan and valsartan, when given simultaneously at equimolar concentrations, strongly inhibit the hPEPT1-specific uptake of cefadroxil. Such drugdrug interactions depend on the affinity constants of the drugs in relation to their effective concentrations in the intestinal lumen. The affinity constants of many drugs for hPEPT1 are known (for review, see tables in Brandsch et al., 2008) . The constants of four sartans have been measured in this study. According to Dominiak (1999) , the daily doses of sartans given during therapy are as follows: losartan 50 to 100 mg, valsartan 80 to 160 mg, eprosartan 600 to 800 mg, and irbesartan 75 to 300 mg. Estimating the local drug concentration in the luminal intestinal fluid that comes in contact with the epithelial cell layer, concentrations of around 50 to 500 M are conceivable. This concentration range corresponds to the constants of the drugs for Gly-Sar uptake inhibition (20 -2000 M) . Because PEPT1 is the predominant membrane protein that mediates uptake of p.o. available ␤-lactam antibiotics, valacyclovir, and other peptidomimetic drugs, it could be speculated that sartans, when given simultaneously for a longer treatment period, may alter the bioavailability and pharmacokinetics of PEPT1 substrates. On the other hand, depending on their affinity and their respective local concentration, PEPT1 substrates can reduce the interaction potential of sartans with the carrier protein.
Whether such effects occur at the human intestinal epithelium and whether there might be consequences for drug pharmacokinetics have to be investigated in vivo.
